 Connection
Richard Hamman to Hypoglycemic Agents
This is a "connection" page, showing publications Richard Hamman has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.722 |
|
|
|
-
Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF, Goldberg RB. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014 Sep; 37(9):2622-31.
Score: 0.078
-
Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med. 2014 09; 31(9):1064-8.
Score: 0.077
-
Lawrence JM, Black MH, Zhang JL, Slezak JM, Takhar HS, Koebnick C, Mayer-Davis EJ, Zhong VW, Dabelea D, Hamman RF, Reynolds K. Validation of pediatric diabetes case identification approaches for diagnosed cases by using information in the electronic health records of a large integrated managed health care organization. Am J Epidemiol. 2014 Jan 01; 179(1):27-38.
Score: 0.074
-
Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012 Jun 16; 379(9833):2243-51.
Score: 0.068
-
Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause. 2011 Aug; 18(8):857-68.
Score: 0.064
-
Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14; 374(9702):1677-86.
Score: 0.056
-
Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007 Apr; 92(4):1502-9.
Score: 0.046
-
Herman WH, Hoerger TJ, Hicks K, Brandle M, Sorensen SW, Zhang P, Engelgau MM, Hamman RF, Marrero DG, Ackermann RT, Ratner RE. Managing people at high risk for diabetes. Ann Intern Med. 2006 Jan 03; 144(1):66-7; author reply 67-8.
Score: 0.043
-
Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
Score: 0.041
-
Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Mar 01; 142(5):323-32.
Score: 0.041
-
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 07; 346(6):393-403.
Score: 0.033
-
Hamman RF, Horton E, Barrett-Connor E, Bray GA, Christophi CA, Crandall J, Florez JC, Fowler S, Goldberg R, Kahn SE, Knowler WC, Lachin JM, Murphy MB, Venditti E. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes. 2015 Mar; 64(3):989-98.
Score: 0.020
-
Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, Meigs JB, Altshuler D, Knowler WC, Florez JC. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011 Apr; 60(4):1340-8.
Score: 0.015
-
Dabelea D, D'Agostino RB, Mason CC, West N, Hamman RF, Mayer-Davis EJ, Maahs D, Klingensmith G, Knowler WC, Nadeau K. Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia. 2011 Jan; 54(1):78-86.
Score: 0.015
-
Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009 Sep; 32(9):1583-8.
Score: 0.014
-
Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes (Lond). 2008 Oct; 32(10):1537-44.
Score: 0.013
-
Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007 Apr; 56(4):1153-9.
Score: 0.012
-
Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan DM, Altshuler D. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007 Feb; 56(2):531-6.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|